H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price target The firm sees potential for the company’s clinical-stage antiviral pipeline to deliver “significant value” in collaboration with Gilead Sciences (GILD).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences Completes $175 Million Equity Financing
- Assembly Biosciences Announces Positive Phase 1b Results
- Assembly Biosciences announces pricing of $175M in equity financings
- Assembly Biosciences reports interim results from phase 1b study of ABI-5366
- Assembly Biosciences Reports Q2 2025 Progress and Financials